Efficacy of immune checkpoint inhibitors combined with bevacizumab in MSS/pMMR advanced colorectal cancer after first-line treatment failure

Efficacy of immune checkpoint inhibitors combined with bevacizumab in MSS/pMMR advanced colorectal cancer after first-line treatment failure

ObjectiveTo investigate the effects of a PD-1 inhibitor combined with a bevacizumab monoclonal antibody on tumor immune cells in patients with first-line treatment failure in MSS/pMMR advanced colorectal cancer.MethodsControl group consisted of 50 patients treated with the FOLFIRI combined with Beva...

Full description

Bibliographic Details
Main Authors: Xiaoqian Chen, Wenkui Li, Xiaogai Lei, Zhanhong Li, Qijing Guo, Xinfu Ma, Yushuang Luo, Liang Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-08-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitors
bevacizumab
colorectal cancer
cytotoxic T lymphocytes
tumor-associated macrophages
cancer-associated fibroblasts
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1429095/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1429095/full

Similar Items